Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity

IVIG Helps Alleviate Chemo-Induced Neuropathy

Intravenous immunoglobulin (IVIG), has shown promising potential in alleviating chemotherapy-induced neuropathy--a common and often debilitating side effect of cancer treatment. Neuropathy, which results from nerve damage caused by certain chemotherapy drugs, can lead to persistent pain, numbness, tingling, and loss of motor function. IVIG works by modulating the immune response and reducing inflammation around damaged nerves, offering a protective and reparative effect. It has been used successfully in various autoimmune and inflammatory neuropathies, and emerging research and case reports suggest it may also help preserve nerve function in cancer patients undergoing chemotherapy. By preventing or minimizing neuropathy, IVIG offers patients the possibility of completing their treatment with fewer long-term complications and a better quality of life.

The National Library of Medicine published a study demonstrating that human intravenous immunoglobulin (IVIG) significantly alleviates neuropathic symptoms in a rat model of paclitaxel-induced peripheral neurotoxicity. These findings support what many patients and clinicians have long hoped: that IVIG may protect against on of chemotherapy's most painful and disabling side effects. It's time to fund the clinical trials needed to bring this promising therapy to the patients who need it most.

Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity

https://pmc.ncbi.nlm.nih.gov/articles/PMC7865319/